Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).

[1]  R. Califf,et al.  Association between angiographic complications and clinical outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention: an EARLY ACS (Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome) angiographic substudy. , 2012, JACC. Cardiovascular interventions.

[2]  G. Stone,et al.  Intraprocedural thrombotic events during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes are associated with adverse outcomes: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. , 2012, Journal of the American College of Cardiology.

[3]  R. Califf,et al.  Association between Angiographic Complications and Clinical Outcomes among Patients with Acute Coronary Syndrome undergoing Percutaneous Coronary Intervention: An EARLY ACS Angiographic Substudy , 2012 .

[4]  V. Hasselblad,et al.  Upstream Use of Small-Molecule Glycoprotein IIb/IIIa Inhibitors in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview of Randomized Clinical Trials , 2011, Circulation. Cardiovascular quality and outcomes.

[5]  H. Suryapranata,et al.  Meta-analysis of randomized trials of glycoprotein IIb/IIIa inhibitors in high-risk acute coronary syndromes patients undergoing invasive strategy. , 2011, The American journal of cardiology.

[6]  F. Prati,et al.  Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study. , 2010, JACC. Cardiovascular interventions.

[7]  R. Califf,et al.  Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.

[8]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[9]  W. Gibson,et al.  Intracoronary pharmacotherapy in the management of coronary microvascular dysfunction , 2008, Journal of Thrombosis and Thrombolysis.

[10]  G. Biondi-Zoccai,et al.  Early glycoprotein IIb–IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis , 2008, Heart.

[11]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[12]  L. Newby,et al.  Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE). , 2007, The American journal of cardiology.

[13]  J. Ware,et al.  Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY Timing trial. , 2007, JAMA.

[14]  R. Califf,et al.  The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro , 2005, American heart journal.

[15]  G. Montalescot,et al.  Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. , 2004, JAMA.

[16]  A. Yeung,et al.  Adjunctive Platelet Glycoprotein IIb/IIIa Receptor Inhibition With Tirofiban Before Primary Angioplasty Improves Angiographic Outcomes: Results of the TIrofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) Pilot Trial , 2003, Circulation.

[17]  E. Braunwald,et al.  Relationship of the TIMI Myocardial Perfusion Grades, Flow Grades, Frame Count, and Percutaneous Coronary Intervention to Long-Term Outcomes After Thrombolytic Administration in Acute Myocardial Infarction , 2002, Circulation.

[18]  M. Morice,et al.  Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. , 2001, The New England journal of medicine.

[19]  E. Antman,et al.  Combination Therapy With Abciximab Reduces Angiographically Evident Thrombus in Acute Myocardial Infarction: A TIMI 14 Substudy , 2001, Circulation.

[20]  E. Braunwald,et al.  TIMI frame count: a quantitative method of assessing coronary artery flow. , 1996, Circulation.

[21]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.